JPMorgan Chase & Co. Boosts Holdings in Omeros Corporation $OMER

JPMorgan Chase & Co. grew its position in Omeros Corporation (NASDAQ:OMER) by 1,201.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 416,153 shares of the biopharmaceutical company’s stock after buying an additional 384,168 shares during the period. JPMorgan Chase & Co. owned 0.59% of Omeros worth $1,706,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. grew its stake in shares of Omeros by 113.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 5,677 shares during the period. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Omeros in the 2nd quarter valued at approximately $32,000. Tower Research Capital LLC TRC grew its stake in shares of Omeros by 829.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 11,971 shares during the period. Sei Investments Co. purchased a new stake in shares of Omeros in the 2nd quarter valued at approximately $40,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Omeros by 86.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,929 shares of the biopharmaceutical company’s stock valued at $90,000 after buying an additional 10,161 shares during the period. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Wall Street Zen raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright increased their price target on shares of Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Zacks Research raised shares of Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. D. Boral Capital restated a “buy” rating and issued a $36.00 price objective on shares of Omeros in a report on Tuesday, January 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $40.33.

Insider Activity at Omeros

In other news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 12.90% of the company’s stock.

Omeros Stock Performance

Shares of OMER stock opened at $10.98 on Wednesday. The firm’s 50 day moving average price is $11.31 and its 200-day moving average price is $10.01. Omeros Corporation has a one year low of $2.95 and a one year high of $17.65. The firm has a market cap of $790.56 million, a P/E ratio of -21.96 and a beta of 2.53.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Tuesday, March 31st. The biopharmaceutical company reported $3.14 EPS for the quarter, topping the consensus estimate of ($0.55) by $3.69. As a group, research analysts predict that Omeros Corporation will post -3.09 EPS for the current fiscal year.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.